Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 11/20 | 0.58 |
| ▸ | CDC25B | P30305 | 8/20 | 0.58 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.54 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.54 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.54 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.54 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.54 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.54 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.54 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.54 |
| ▸ | TACR2 | P21452 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5959877 | 1.00 | NT5E (0.62) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL16267818 | 1.00 | NT5E (0.62) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL4107734 | 1.00 | NT5E (0.62) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL8359080 | 1.00 | NT5E (0.62) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL8359084 | 1.00 | NT5E (0.62) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL8579200 | 1.00 | NT5E (0.62) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL14120091 | 1.00 | NT5E (0.62) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL4107740 | 1.00 | NT5E (0.62) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL20473799 | 1.00 | NT5E (0.62) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL16267817 | 1.00 | NT5E (0.62) | NT5EPTPN1CDC25BPTPN2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240025936-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-11634447-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230033327-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY | 2023-02-02 | — | — | US | disclosed |
| US-20220135609-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMA (US) | 2022-05-05 | — | — | US | disclosed |
| US-10669298-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190211045-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | UNIV WASHINGTON (US) | 2019-07-11 | — | — | US | disclosed |
| US-20190106450-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS INCORPORATED | 2019-04-11 | — | — | US | disclosed |
| EP-3388441-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-2935302-B1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMA (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9963478-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-05-08 | — | — | US | disclosed |
| US-9957289-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2018-05-01 | — | — | US | disclosed |
| US-9598454-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-21 | — | — | US | disclosed |
| US-9567362-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160235775-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2016-08-18 | — | — | US | disclosed |
| EP-2935302-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20140243283-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2014100158-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230033327-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | FPR1, VIL1, VIP | NT5E 1597/4885PTPN1 2342/4885CDC25B 4252/4885 |
| US-20140243283-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | MPI, MANBA, MAN2A1 | NT5E 829/4885PTPN1 2363/4885CDC25B 1271/4885 |
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | IL2, IL4, PBK | NT5E 1818/4885PTPN1 3366/4885CDC25B 518/4885 |
| US-20160235775-A1 | Mannose Derivatives for Treating Bacterial Infections | MPI, MANBA, MAN2A1 | NT5E 829/4885PTPN1 2363/4885CDC25B 1271/4885 |
| US-20190106450-A1 | Mannose Derivatives for Treating Bacterial Infections | MPI, MANBA, MAN2A1 | NT5E 829/4885PTPN1 2363/4885CDC25B 1271/4885 |
| US-20240025936-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | IL2, PBK, IL4 | NT5E 1691/4885PTPN1 3338/4885CDC25B 560/4885 |
| US-20220135609-A1 | Mannose Derivatives for Treating Bacterial Infections | MPI, MANBA, MAN2A1 | NT5E 829/4885PTPN1 2363/4885CDC25B 1271/4885 |
| US-20190211045-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, GUSB | NT5E 533/4885PTPN1 4164/4885CDC25B 3360/4885 |
| US-10669298-B2 | Mannose derivatives for treating bacterial infections | MPI, MANBA, MAN2A1 | NT5E 829/4885PTPN1 2363/4885CDC25B 1271/4885 |
| US-11634447-B2 | Mannose derivatives for treating bacterial infections | MPI, MANBA, MAN2A1 | NT5E 829/4885PTPN1 2363/4885CDC25B 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.